Apoptosis induced by nucleosides in the human hepatoma HepG2

Table 1 Effects of nucleosides on HepG2 cell viability by MTS assay¹

Treatment	Inosine (%)	Cytidine (%)	Uridine (%)	Thymidine (%)	Adenosine(%)	Guanosine(%)
0 mmol/L	103.9±3.5a	101.8±1.6a	103.5±3.5a	102.2±1.9a	101.3±1.2a	103.1±2.7a
7.5 mmol/L	94.0±1.2a	92.0±3.8 a	100.6±6.6a	101.5±5.1a
15 mmol/L	69.5±1.8 a	75.6±1.7 a	99.1±2.8a	99.0±0.3a
30 mmol/L	67.7±0.7a	61.4±5.9a	86.1±1.3a	84.5±3.2a
0.1 mmol/L					93.0±5.2a	86.3±3.5a
0.3 mmol/L					80.9±2.0a	89.4±2.1a
0.5 mmol/L					78.4±1.8a	86.3±3.3a

¹ Cells were incubated with different treatments for 12 h. Cell viability was measured with MTS assay kits. Values are expressed as the mean±SD of six independent experiments.

^aP<0.05 vs 0 mmol/L.

Table 2 Effects of nucleosides on the cell cycle progression, caspas-3 activity and sFas-L content in HepG2 cells¹

Treatment	Control	Inosine	Cytidine	Uridine	Thymidine	Adenosine	Gaunosine
SubG1 (%)	2.6±0.8a	3.2±0.3a	6.9±0.2a	6.5±1.5a	26.8±2.3a	9.6±1.5a	5.7±1.2a
G0/G1(%)	67.7±1.1a	69.2±0.1a	74.1±1.3a	84.8±2.6a	54.4±1.8a	64.8±1.4a	68.0±1.9a
S (%)	15.7±0.0a	18.8±0.3a	8.5±0.2a	3.1±0.3a	12.0±0.2a	10.6±0.4a	17.3±0.7a
G2/M (%)	14.0±1.9a	8.8±0.1a	10.5±1.0a	5.7±0.8a	6.8±0.8a	15.0±0.9a	9.0±1.3a
Caspase-3 (%)2	100±0a	101±5a	97±6a	98±5a	148±2a	104±4a	100±3a
sFas-L (pg/mL)	0.11±0.01a	0.14±0.01a	0.08±0.03a	0.15±0.03a	0.17±0.02a	0.15±0.07a	0.10±0.03a

¹Cells were treated with or without nucleosides for 12 h. The contents of inosine, cytidine, uridine, and thymidine in the mediums were 30 mmol/L, respectively, and, the contents of adenosine and guanosine were 0.5 mmol/L. Values are expressed as the mean±SD of four independent experiments.

^aP<0.05 vs others.

²Caspase-3 activity was shown as percentage to compare with control group.